2017
Dynamic contrast‐enhanced MRI perfusion for differentiating between melanoma and lung cancer brain metastases
Hatzoglou V, Tisnado J, Mehta A, Peck KK, Daras M, Omuro AM, Beal K, Holodny AI. Dynamic contrast‐enhanced MRI perfusion for differentiating between melanoma and lung cancer brain metastases. Cancer Medicine 2017, 6: 761-767. PMID: 28303695, PMCID: PMC5387174, DOI: 10.1002/cam4.1046.Peer-Reviewed Original ResearchConceptsMelanoma brain metastasesNSCLC brain metastasesLung cancer brain metastasesBrain metastasesCancer brain metastasesCell lung cancer brain metastasesDCE-MRIPrimary brain tumorsDifferent primary sitesImportant clinical implicationsMann-Whitney U testVolume transfer coefficientTumor histologyMultiple malignanciesMRI perfusionBrain tumorsMetastasisPrimary siteConventional MRIClinical implicationsPerfusion parametersTumor microvasculatureROC analysisU testPlasma volume
2015
Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non–small cell lung cancer
Nayak L, DeAngelis LM, Robins HI, Govindan R, Gadgeel S, Kelly K, Rigas JR, Peereboom DM, Rosenfeld SS, Muzikansky A, Zheng M, Urban P, Abrey LE, Omuro A, Wen PY. Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non–small cell lung cancer. Cancer 2015, 121: 4165-4172. PMID: 26308485, PMCID: PMC5941922, DOI: 10.1002/cncr.29636.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerProgressive brain metastasesBrain metastasesCell lung cancerAdverse eventsStudy drugLung cancerGrade 3/4 adverse eventsMulticenter phase 2 studyNSCLC brain metastasesSteady-state distribution volumePhase 1/2 studyRecurrent brain metastasesPhase 2 studyProgression-free survivalFirst prospective studyConcentration-time curvePrimary endpointAdult patientsOverall survivalPulmonary embolismMedian agePeripheral neuropathyMedian timeProspective study